Bizarre Patents
A fork with timer for providing a cue to a user after an elapsed period of time for indicating that another bite of food using the fork may be taken.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Application No. | Application Title | Issue Date |
| 20120128771 | TIMED, PULSATILE RELEASE SYSTEMS A unit multiparticulate dosage form for delivering one or more basic, active pharmaceutical ingredients into the body in need of such medications to achieve target PK (pharmacokinetics) profiles is described. The dosage form comprises one or more multicoated drug partic... | 05/24/2012 |
| 20120128780 | NANOPARTICULATE BISPHOSPHONATE COMPOSITIONS Nanoparticulate bisphosphonate compositions, having an effective average particle size of less than 2000 nm, are described. The compositions are useful in treating bone resorption in a mammal.... | 05/24/2012 |
| 20120128764 | CONTROLLED-RELEASE COMPOSITIONS COMPRISING A PROTON PUMP INHIBITOR The present invention relates to pharmaceutical compositions, and methods of preparing such compositions, comprising one or more populations of controlled-release particles comprising one or more proton pump inhibitors. The present invention also relates to pharmaceutic... | 05/24/2012 |
| 20120082729 | QUICK DISSOLVE COMPOSITIONS AND TABLETS BASED THEREON The invention provides a composition useful for making oral dosage forms capable of dissolving in the mouth in less than 40 seconds without the need for a conventional super disintegrant and having a friability of less than 1%; wherein the composition includes liquiflas... | 04/05/2012 |
| 20120082718 | Morphine Formulations Described is a pellet composition comprising a core element comprising morphine sulfate, a filler and a binder, wherein the morphine sulfate, calculated as the anhydrous form, comprises about 50 wt % to about 85 wt % of the total weight of the core element; and a coatin... | 04/05/2012 |
| 20120045506 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION WITH RESISTANCE AGAINST THE INFLUENCE OF ETHANOL EMPLOYING A COATING COMPRISING NEUTRAL VINYL POLYMERS AND EXCIPIENTS The invention relates to a controlled release pharmaceutical composition, comprising a core, comprising a pharmaceutical active ingredient, whereby the core is coated by an ethanol resistance conferring coating layer which has the effect of conferring the release profil... | 02/23/2012 |
| 20120040008 | PHARMACEUTICAL COMPOSITIONS OF METABOTROPIC GLUTAMATE 5 RECEPTOR (MGLU5) ANTAGONISTS Pharmaceutical compositions of metabotropic glutamate 5 receptor (mGlu5) antagonists or a pharmacologically acceptable salt thereof are disclosed. The compositions contain the therapeutic active compound with non-ionic polymer and ionic polymer, binder and fillers in ei... | 02/16/2012 |
| 20120027864 | COATED DRUG DELIVERY FORMULATIONS The invention relates generally to methods of making formulations for delivering biological agents to a patient. In one aspect, proliposomal drug-delivery systems for medicaments are provided. In another aspect, coated proliposomal formulations for poorly water soluble ... | 02/02/2012 |
| 20120027856 | PHARMACEUTICAL PRODUCT COMPRISING YEAST A pharmaceutical product containing an active pharmaceutical ingredient and having a controllable release of the active pharmaceutical ingredient. The pharmaceutical product comprises yeast that is capable of fermentation. The carbon dioxide production of the fermentati... | 02/02/2012 |
| 20120015038 | ENTERICALLY COATED CYSTEAMINE, CYSTAMINE AND DERIVATIVES THEREOF The disclosure provides oral cysteamine and cystamine formulations useful for treating cystinosis and neurodegenerative diseases and disorders. The formulations provide controlled release compositions that improve quality of life and reduced side-effects.... | 01/19/2012 |
| 20120003303 | ORAL ENTERIC ANTIDEPRESSANT FORMULATION Pharmaceutical presentations of phenoxathiin-based MAO-A inhibitors are disclosed whereby the MAO receptors are protected from binding to active ingredient in the stomach. Particular phenoxathiin-based MAO-A inhibitors include those of the following formula: (I) wherein... | 01/05/2012 |
| 20110311619 | PHARMACEUTICAL FORMULATION OF NANONISED FENOFIBRATE The invention relates to a pharmaceutical formulation of nanonised fenofibrate, to a method for preparing same, and to the uses thereof.... | 12/22/2011 |
| 20110311626 | CONTROLLED RELEASE COMPOSITIONS COMPRISING ANTI-CHOLINERGIC DRUGS The present invention provides compositions comprising dicyclomine, or salts, and/or solvates and methods of making and using the compositions to treat intestinal hypermotility or Irritable Bowel Syndrome (IBS). The present invention also provides once-a-day orally disi... | 12/22/2011 |
| 20110300224 | TASTE MASKED DOSAGE FORM OF PHARMACEUTICALLY ACCEPTABLE SALT OF ESCITALOPRAM A taste masked dosage form of pharmaceutical acceptable salt of escitalopram comprising (a) resin complex of pharmaceutical acceptable salt of escitalopram and cationic exchange resin or adsorbing or coating non-pareil seeds or inert particles with a mixture of pharmace... | 12/08/2011 |
| 20110293729 | NOVEL COMPOSITION BASED ON GAMMA-HYDROXYBUTYRIC ACID The present invention relates to a granule of gamma-hydroxybutyric acid or of one of its pharmaceutically acceptable salts, characterized in that it comprises a solid core on which the gamma-hydroxybutyric acid or one of its salts is supported.... | 12/01/2011 |
| 20110287099 | Sustained-release formulations of topiramate Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to releas... | 11/24/2011 |
| 20110280945 | NOVEL METHOD FOR THE PREPARATION OF GRANULATES OF ACTIVE CONSTITUENTS, AND GRANULATES AS OBTAINED The present invention relates to a method for preparing a granulate of at least two active principles, including a step of applying said active principles to a solid particulate medium by dusting, said active principles not being plant extracts.... | 11/17/2011 |
| 20110274762 | Prolonged Release Formulations Comprising an 2-Oxo-1-Pyrrolidine Derivate The present invention relates to a pharmaceutical composition comprising Brivaracetam or Seletracetam as active ingredient, the invention relates specifically to a prolonged release formulation made of granules containing the active ingredient in their inner core.... | 11/10/2011 |
| 20110256218 | CONTROLLED RELEASE COMPOSITIONS COMPRISING MECLIZINE OR RELATED PIPERAZINE DERIVATIVES The present invention provides pharmaceutically acceptable compositions for once-daily dosing comprising a piperazine derivative of H1-receptor antagonists, or its salt, and/or solvate and methods of making and using the compositions in the treatment of treat... | 10/20/2011 |
| 20110256229 | RAPID-ACTING PHARMACEUTICAL COMPOSITION A pharmaceutical composition for the treatment of acute disorders is described. The composition comprises an essentially water-free, ordered mixture of at least one pharmaceutically active agent in the form of microparticles which are adhered to the surfaces of carrier ... | 10/20/2011 |
| 20110250281 | Fexofenadine Microcapsules and Compositions Containing Them The present invention provides a pharmaceutical composition comprising taste-masked immediate release microcapsules which comprise fexofenadine and a water-insoluble polymer coating. These microcapsules and the pharmaceutical compositions comprising them have suitable d... | 10/13/2011 |
| 20110244051 | PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF OVERACTIVE BLADDER Disclosed herein are pharmaceutical compositions comprising a plurality of first beads each comprising: a core; a first layer comprising pilocarpine or a pharmaceutically acceptable salt thereof; and a second layer comprising a first polymer. Also disclosed are pharmace... | 10/06/2011 |
| 20110244050 | PULSED-RELEASE SILDENAFIL COMPOSITION AND METHOD FOR PREPARING SAID COMPOSITION The present invention relates to a pulsed-release sildenafil pharmaceutical composition comprising an immediate release fraction containing from 5 to 100 mg of sildenafil and a controlled release fraction containing from 25 to 150 mg of sildenafil, wherein the controlle... | 10/06/2011 |
| 20110244049 | COMPOSITIONS COMPRISING 4-(2-(5-BROMO-4-(1-CYCLOPROPYLNAPHTHALEN-4-YL)-4H-1,2,4-TRIAZOL-3-YLTHIO)ACETAMIDO)-3-CHLOROBENZOIC ACID AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, AND METHODS FOR PREPARING AND USING SAME The present invention relates to compositions comprising 4-(2-(5-bromo-4-(1-cyclopropylnaphthalen-4-yl)-4H-1,2,4-triazol-3-ylthio)acetamido)-3-chlorobenzoic acid or pharmaceutically acceptable salts thereof, and to the preparation and use of such compositions, in partic... | 10/06/2011 |
| 20110236494 | CIPROFLOXACIN ORAL SUSPENSION The present invention relates to oral taste masked pharmaceutical composition comprising ciprofloxacin or salts or esters thereof. It further relates to processes of preparing it.... | 09/29/2011 |
| 20110236493 | POROUS MATERIALS A consumer care composition or a food composition comprising a mesoporous microparticulate material wherein at least some of the pores of the material are loaded with at least one ingredient and the loaded mesoporous microparticulate material is encapsulated by a cappin... | 09/29/2011 |
| 20110229562 | PH-DEPENDENT CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION FOR NON-OPIOIDS WITH RESISTANCE AGAINST THE INFLUENCE OF ETHANOL The invention relates to a pH-dependent controlled release pharmaceutical composition, comprising at least one pharmaceutical active ingredient, with the exception of opioids, wherein the core is coated at least by one coating layer, controlling the release of the pharm... | 09/22/2011 |
| 20110217383 | PH-DEPENDENT CONTROLLED RELEASE PHARMACEUTICAL OPIOID COMPOSITION WITH RESISTANCE AGAINST THE INFLUENCE OF ETHANOL The invention relates to a pH-dependent controlled release pharmaceutical composition, comprising a core, and an opioid, wherein the core is coated at least by one coating layer, controlling the release of the pharmaceutical composition, wherein the coating layer compri... | 09/08/2011 |
| 20110212171 | TASTE MASKED TOPIRAMATE COMPOSITION AND AN ORALLY DISINTEGRATING TABLET COMPRISING THE SAME In various embodiments, the present invention is directed to a taste masked pharmaceutical composition comprising a therapeutically effective amount of taste masked sulfamate-substituted monosaccharide particles comprising a sulfamate-substituted monosaccharide or a pha... | 09/01/2011 |
| 20110200681 | Abuse Resistant Drug Formulation A pharmaceutical composition may include a granulate which may include at least one active pharmaceutical ingredient susceptible to abuse by an individual mixed with at least two materials, a first material that is substantially water insoluble and at least partially al... | 08/18/2011 |
| 20110165257 | COATED DRUG SPHEROIDS AND USES THEREOF FOR ELIMINATING OR REDUCING CONDITIONS SUCH AS EMESIS AND DIARRHEA The present invention provides an oral pharmaceutical formulation comprising coated spheroids of a kinase inhibitor such as neratinib, which formulation is designed to reduce or eliminate side effects associated with existing oral formulations of kinase inhibitors.... | 07/07/2011 |
| 20110150997 | ELVUCITABINE PHARMACEUTICAL COMPOSITIONS The invention provides novel pharmaceutical compositions of Elvucitabine. The invention also provides pharmaceutical compositions and oral dosage forms having unique physical-chemical properties.... | 06/23/2011 |
| 20110142933 | Controlled Release Dosage Form of Tacrolimus A controlled release dosage form of tacrolimus, comprising a solid dispersion of tacrolimus, wherein a controlled release base, which is selected from the group consisting of a water-soluble macromolecule, a gum base, and a membrane forming agent and does not form the s... | 06/16/2011 |
| 20110129539 | ORAL PHARMACEUTICAL FORMULATION IN THE FORM OF AN AQUEOUS SUSPENSION OF MICROCAPSULES FOR MODIFIED RELEASE OF AMOXICILLIN The invention concerns liquid pharmaceutical formulations, for oral delivery, with modified release of amoxicillin and consisting of suspensions of coated particles of amoxicillin (microcapsules). The microcapsules constituting the dispersed phase of the suspension are ... | 06/02/2011 |
| 20110129530 | Compressible-Coated Pharmaceutical Compositions and Tablets and Methods of Manufacture There is provided a method for preparing a pharmaceutical composition comprising compressible coated, taste-masked and/or controlled-release coated drug-containing particles, rapidly-dispersing microgranules comprising a disintegrant and a sugar alcohol, a saccharide, o... | 06/02/2011 |
| 20110129538 | PROCESS FOR PREPARING ORALLY ADMINISTERED DABIGATRAN FORMULATIONS The invention relates to an improved process for preparing a new medicament formulation of the active substance dabigatran etexilate of formula I in the form of the methanesulphonic acid salt thereof, and thi... | 06/02/2011 |
| 20110123613 | EXTENDED-RELEASE DOSAGE FORM Provided are pharmaceutical formulations comprising sustained release particles each having an inner core bead comprising an active pharmaceutical ingredient an intermediate coating substantially surrounding the inner core bead, and an outer coating substantially surrou... | 05/26/2011 |
| 20110123633 | STABLE DIGESTIVE ENZYME COMPOSITIONS Compositions of the present invention, comprising at least one digestive enzyme (e.g., pancrelipase) are useful for treating or preventing disorders associated with digestive enzyme deficiencies. The compositions of the present invention can comprise a plurality of coat... | 05/26/2011 |
| 20110123634 | STABLE DIGESTIVE ENZYME COMPOSITIONS Compositions of the present invention, comprising at least one digestive enzyme (e.g., pancrelipase) are useful for treating or preventing disorders associated with digestive enzyme deficiencies. The compositions of the present invention can comprise a plurality of coat... | 05/26/2011 |
| 20110117205 | ORAL PHARMACEUTICAL FORMULATION IN THE FORM OF AQUEOUS SUSPENSION FOR MODIFIED RELEASE OF ACTIVE PRINCIPLE(S) The invention relates to liquid pharmaceutical formulations for oral administration with the modified release of active principle(s), excluding amoxicillin, said formulations consisting of suspensions of coated particles of active principles (microcapsules). According t... | 05/19/2011 |
